An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PDL BioPharma, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Previous participation in a visilizumab study of IVSR-UC.
Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.
You may not be if
Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent.
For U.S. sites, unwilling or unable to provide authorization to use protected health information.
Clareo Health | An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
